238 related articles for article (PubMed ID: 24354764)
1. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.
Lotta LA; Valsecchi C; Pontiggia S; Mancini I; Cannavò A; Artoni A; Mikovic D; Meloni G; Peyvandi F
J Thromb Haemost; 2014; 12(3):329-36. PubMed ID: 24354764
[TBL] [Abstract][Full Text] [Related]
2. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F;
Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777
[TBL] [Abstract][Full Text] [Related]
3. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
Thomas MR; de Groot R; Scully MA; Crawley JT
EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
[TBL] [Abstract][Full Text] [Related]
4. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
[TBL] [Abstract][Full Text] [Related]
6. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Starke R; Machin S; Scully M; Purdy G; Mackie I
Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
[TBL] [Abstract][Full Text] [Related]
7. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
Zheng XL
J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
[TBL] [Abstract][Full Text] [Related]
8. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
Ferrari S; Palavra K; Gruber B; Kremer Hovinga JA; Knöbl P; Caron C; Cromwell C; Aledort L; Plaimauer B; Turecek PL; Rottensteiner H; Scheiflinger F
Haematologica; 2014 Apr; 99(4):779-87. PubMed ID: 24241492
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
Tsai HM
Kidney Int Suppl; 2009 Feb; (112):S11-4. PubMed ID: 19180123
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
11. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
Shelat SG; Smith P; Ai J; Zheng XL
J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212
[TBL] [Abstract][Full Text] [Related]
13. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
14. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission.
Groot E; Fijnheer R; Sebastian SA; de Groot PG; Lenting PJ
J Thromb Haemost; 2009 Jun; 7(6):962-9. PubMed ID: 19548905
[TBL] [Abstract][Full Text] [Related]
15. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura.
Tsai HM; Raoufi M; Zhou W; Guinto E; Grafos N; Ranzurmal S; Greenfield RS; Rand JH
Thromb Haemost; 2006 May; 95(5):886-92. PubMed ID: 16676082
[TBL] [Abstract][Full Text] [Related]
16. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
Sadler JE
Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
[TBL] [Abstract][Full Text] [Related]
17. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA).
Rieger M; Ferrari S; Kremer Hovinga JA; Konetschny C; Herzog A; Koller L; Weber A; Remuzzi G; Dockal M; Plaimauer B; Scheiflinger F
Thromb Haemost; 2006 Feb; 95(2):212-20. PubMed ID: 16493480
[TBL] [Abstract][Full Text] [Related]
18. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
19. Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.
Li D; Xiao J; Paessler M; Zheng XL
Thromb Haemost; 2011 Nov; 106(5):947-58. PubMed ID: 21901237
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers].
Liu F; Feys HB; Dong NZ; Bai X; Vanhoorelbeke K; Deckmyn H; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):154-7. PubMed ID: 16792913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
